Current and Future Topics on Prostate Cancer (Ongoing)

Posted On 2020-03-19 06:20:20



This Focused Issue “Current and Future Topics on Prostate Cancer” is edited by Dr. Badrinath Konety from Department of Urology, University of Minnesota, Minneapolis, MN, USA and Dr. Daniel W. Lin from Department of Urology, University of Washington, Seattle, Washington, USA.

Badrinath R. Konety, M.D., M.B.A., is CEO of University of Minnesota Physicians (UMP) and Vice Dean of Clinical Affairs for the University of Minnesota Medical School. He is also a Professor in the Department of Urology and holds the Dougherty Family Chair in Uro-Oncology as well as being the Director of the Institute for Prostate and Urologic Cancers at the University of Minnesota. He is the former chair of the Department of Urology, Associate Director for Clinical Affairs of the Masonic Cancer Center at the University of Minnesota and Associate Dean for Strategy and Innovation of the Medical School.

Badrinath Konety, M.D., completed his residency and American Foundation for Urologic Disease Research Scholar fellowship at the University of Pittsburgh. He also received an MBA from the University of Pittsburgh Katz School of Business. Dr. Konety also completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center.

He has authored or co-authored 250 original publications and numerous book chapters as well as editing a text on bladder cancer. He has been and is principal or co-investigator on grants funded through the Department of Defense, National Institutes of Health, American Geriatrics Society and Center for Disease Control. He received the Jahnigen Career Development Scholar Award, and is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, Societe Internationale D’Urologie and the American Association of Genitourinary Surgeons. He is currently the Past President of the SIU, President of the Society of Academic Urology and Associate Editor of the Journal of Urology.

Dr. Lin is Professor with Tenure and Chief of Urologic Oncology in the Department of Urology, the Director of the Institute for Prostate Cancer Research, and holds the Pritt Family Endowed Chair in Prostate Cancer Research at the University of Washington School of Medicine. Dr. Lin is Full Member (joint) of the Public Health Sciences Division of the Fred Hutchinson Cancer Research Center. Dr. Lin received his undergraduate degree from Stanford University and his medical degree from Vanderbilt University. He completed his urology residency at the University of Washington and urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center, followed by an American Foundation for Urologic Disease (AFUD) Physician Scholar Award at the Fred Hutchinson Cancer Research Center.

Dr. Lin serves on various national committees including the guideline panels for the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA). Dr. Lin was Chair of the Male Genital Panel for the American Joint Commission on Cancer (AJCC) 8th Edition. Dr. Lin is co-Chair of the Prostate Cancer Task Force of the NCI GU Steering Committee and is Chair of the Localized Prostate Cancer Committee for the Southwest Oncology Group (SWOG). Dr. Lin is on the Board of Directors for the Society of Urologic Oncology (SUO) and the SUO Clinical Trials Consortium (SUO-CTC), currently the Treasurer of the SUO.

Dr. Lin’s major basic/translational research interests are in molecular/genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and novel strategies in high-risk prostate cancer. Dr. Lin is the lead PI for the Canary Prostate Active Surveillance Study (PASS) since its inception in 2008. Dr. Lin is also co-PI of the Pacific Northwest Prostate Cancer Specialized Program of Research Excellence (SPORE) and co-Lead of the Prostate Program at the Fred Hutchinson Cancer Research Center. Dr. Lin receives funding from multiple peer-reviewed grants from the National Cancer Institute (NCI) and Department of Defense (DOD).

Focused issue outline:

  1. Editorial
  2. Prostate cancer early detection: screening and risk assessment
  3. Prostate cancer biomarkers to aid in diagnosis
  4. MRI/PET Imaging in elevated PSA and localized prostate cancer
  5. Focal therapy for primary and salvage therapy
  6. Active surveillance: risk assessment and modeling in outcomes
  7. Is precision prostatectomy a real option?
  8. Management of oligometastatic prostate cancer
  9. Advances in prostate cancer radiation therapy
  10. Hormonal manipulation: Options, outcomes and and side effects
  11. Neoadjuvant and adjuvant strategies in high risk disease
  12. Management strategies and outcomes in node-positive prostate cancer
  13. Treatment of hormone-sensitive metastatic prostate cancer
  14. Prostate cancer immunotherapy: current roles and future directions
  15. Sequencing considerations for systemic therapy in metastatic prostate cancer
  16. Next generation imaging in localized and advanced prostate cancer
  17. Lineage plasticity in metastatic castrate-resistant prostate cancer: Implications on treatment and outcomes
  18. Prostate cancer theranostics
  19. Management of prostate cancer in special populations (gay men, gender reaffirmation)

Disclosure:
The focused issue “Current and Future Topics on Prostate Cancer” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Badrinath Konety and Daniel W. Lin are serving as the unpaid Guest Editors for the focused issue.